详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

123| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Shanghai Pulmonary Hospital, Tongji University School of Medicine [2]Shanghai Chest Hospital [3]Fudan University Shanghai Cancer Center [4]Roche (China) Holding Ltd, Shanghai [5]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences [6]The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou [7]Harbin Medical University Cancer Hospital, Harbin [8]Academy of Military Medical Sciences Affiliated Hospital (307 Hospital of People’s Liberation Army) [9]Beijing Chest Hospital [10]Beijing Cancer Hospital [11]Beijing Hospital of Ministry of Health, Beijing [12]Jiangsu Cancer Hospital, Nanjing [13]The Second Xiangya Hospital of Central South University, Changsha [14]Cancer Hospital of Shantou University Medical College, Shantou [15]Affiliated Cancer Hospital of Guangxi Medical University, Nanning [16]West China Hospital, Sichuan University, Chengdu [17]Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, China.

出处：

DOI：

ISSN：

摘要：

The phase III BEYOND trial was undertaken to confirm in a Chinese patient population the efficacy seen with first-line bevacizumab plus platinum doublet chemotherapy in globally conducted studies. Patients age ≥ 18 years with locally advanced, metastatic, or recurrent advanced nonsquamous non-small-cell lung cancer (NSCLC) were randomly assigned to receive carboplatin (area under the curve, 6) intravenously and paclitaxel (175 mg/m(2)) intravenously (CP) on day 1 of each 3-week cycle, for ≤ six cycles, plus placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg intravenously, on day 1 of each cycle, until progression, unacceptable toxicity, or death. The primary end point was progression-free survival (PFS); secondary end points were objective response rate, overall survival, exploratory biomarkers, safety. A total of 276 patients were randomly assigned, 138 to each arm. PFS was prolonged with B+CP versus Pl+CP (median, 9.2 v 6.5 months, respectively; hazard ratio [HR], 0.40; 95% CI, 0.29 to 0.54; P < .001). Objective response rate was improved with B+CP compared with Pl+CP (54% v 26%, respectively). Overall survival was also prolonged with B+CP compared with Pl+CP (median, 24.3 v 17.7 months, respectively; HR, 0.68; 95% CI, 0.50 to 0.93; P = .0154). Median PFS was 12.4 months with B+CP and 7.9 months with Pl+CP (HR, 0.27; 95% CI, 0.12 to 0.63) in EGFR mutation-positive tumors and 8.3 and 5.6 months, respectively (HR, 0.33; 95% CI, 0.21 to 0.53), in wild-type tumors. Safety was similar to previous studies of B+CP in NSCLC; no new safety signals were observed. The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. © 2015 by American Society of Clinical Oncology.

基金：

语种：

高被引：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2015]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 42.1 最新[2023版] 37.4 最新五年平均 20.982 出版当年[2015版] 18.021 出版当年五年平均 18.443 出版前一年[2014版] 24.008 出版后一年[2016版]

第一作者：

第一作者机构： [1]Shanghai Pulmonary Hospital, Tongji University School of Medicine [*1]Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433 China

通讯作者：

通讯机构： [1]Shanghai Pulmonary Hospital, Tongji University School of Medicine [*1]Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433 China

推荐引用方式(GB/T 7714)：

APA：

MLA：

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. $(function () { $("[data-toggle='tooltip']").tooltip(); });

文献详情

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.